Invezz

Mangoceuticals (MGRX)

Nasdaq Market Open

Mangoceuticals, Inc. is a men’s wellness company that markets health products and services through a telemedicine-driven model. The company’s commercial approach is built around direct-to-consumer access, online customer onboarding and pharmacy fulfillment, allowing patients to seek treatment discreetly without relying solely on traditional in-person healthcare channels.

Its best-known offering is associated with men’s sexual health, including Mango ED-branded products that may be prescribed following a telehealth consultation where appropriate. The company does not simply sell over-the-counter goods; its platform is designed to connect consumers with licensed medical providers and, when a prescription is issued, with pharmacy partners that handle fulfillment and distribution. This structure places Mangoceuticals within the growing digital health market, where convenience, privacy and consumer branding are important parts of the customer experience.

Mangoceuticals focuses on wellness categories that are often underserved by conventional healthcare marketing or that carry stigma for consumers. By using an online model, the company seeks to reduce friction in areas such as erectile dysfunction and related men’s health concerns. Its business depends on digital marketing, customer acquisition, regulatory compliance, pharmacy relationships and the ability to maintain trust around medical consultation and prescription handling.

The company operates in a competitive field that includes telehealth platforms, online pharmacies, pharmaceutical brands and men’s health specialists. For investors, Mangoceuticals represents exposure to a smaller consumer health and telemedicine business rather than a diversified pharmaceutical manufacturer. Its prospects are tied to brand recognition, product expansion, patient retention and the broader adoption of online healthcare services.

0.40 USD
+0.02 (+5.89%)

Last updated

Market Cap
6.52M
P/E
P/FCF
P/S
15.74
Enterprise Value
6.35M
Sector
Industry
Address
15110 DALLAS PKWY, SUITE 600, DALLAS, TX, 75248
GlobeNewswire Inc.

Mangoceuticals Announces Lawsuit Seeking Damages Exceeding $73 Million Against Former Technology Consulting and Software Development Firm, Clarity Ventures, Inc.

Mar 17, 2026, 16:00 PM
GlobeNewswire Inc.

Mangoceuticals, Inc. Announces PCT Patent Filing for MGX-0024 Antiviral Technology to Include Inhibiting Respiratory or Orally Acquired Virus Infection in Animals or Birds

Mar 06, 2026, 16:00 PM
GlobeNewswire Inc.

Mangoceuticals Provides Clarification on Launch of Branded GLP-1 Weight-Management Programs

Nov 13, 2025, 19:37 PM
GlobeNewswire Inc.

Mangoceuticals Announces Strategic Entry into High Growth Pouch Industry Through Acquisition of Smokeless Technology IP and Appointment of Tim Corkum Ex Philip Morris Executive to Lead High Growth Pouch Division

Apr 25, 2025, 09:00 AM
Investing.com

Azz Inc. COO acquires $21.2k in company stock By Investing.com - Investing.com Australia

Jul 12, 2024, 14:11 PM
GlobeNewswire Inc.

MangoRx Receives Notice of Acceptance for Patent Application in Australia for Respiratory Illness and Preventive Care Technology

Jun 06, 2024, 08:30 AM
GlobeNewswire Inc.

MangoRx Receives Patent Notice of Allowance in Japan for Revolutionary Preventive Care Technology Acquired from Intramont Technologies

Jun 04, 2024, 16:00 PM
GlobeNewswire Inc.

MangoRx Engages Renown International Digital and Performance Marketing Company Crakmedia to Champion its Digital Marketing Efforts

May 23, 2024, 08:30 AM
PennyStocks

Spotting Penny Stocks Before They Explode, Top Tips

May 22, 2024, 06:52 AM
GlobeNewswire Inc.

MangoRx Reports Revenue Growth of 108% in Q1 2024 Fueled by Amplified Customer Acquisition and Early Market Penetration

May 16, 2024, 16:40 PM
GlobeNewswire Inc.

Mangoceuticals Subsidiary, MangoRx Mexico, Executes Technical Agreement with Mexican Pharmaceutical Manufacturer for Initial Development and Production of its Mango Erectile Dysfunction (ED) Products

Apr 12, 2024, 08:45 AM
GlobeNewswire Inc.

MangoRx Accepting Pre Orders for its “PRIME”, by MangoRx, Powered by Kyzatrex®️ FDA Approved Oral Testosterone Replacement Therapy (TRT) Product

Feb 05, 2024, 08:50 AM
GlobeNewswire Inc.

MangoRx’s Brand and Products to be Featured by Barstool Sports in Week of Programming Around the Biggest Sports Event of the Year on February 11

Jan 19, 2024, 08:00 AM
GlobeNewswire Inc.

Mangoceuticals, Inc. Announces Pricing of $1,200,000 Public Offering

Dec 15, 2023, 10:39 AM
GlobeNewswire Inc.

MANGOCEUTICALS TO INTRODUCE “PRIME”, POWERED BY KYZATREX®️ (CIII TESTOSTERONE UNDECANOATE CAPSULES), FOR AN FDA APPROVED ORAL TESTOSTERONE REPLACEMENT THERAPY (TRT) PRODUCT

Dec 13, 2023, 07:30 AM
GlobeNewswire Inc.

Mangoceuticals Selects TRYBE Labs as its Nationwide Blood Collection and Testing Services Provider

Nov 29, 2023, 08:30 AM
GlobeNewswire Inc.

Mangoceuticals, Inc. Launches Charitable Initiative in Support of Men’s Health Awareness Month

Nov 02, 2023, 09:15 AM
GlobeNewswire Inc.

Mangoceuticals Announces TV Air Dates for Interview Featuring CEO Jacob Cohen on Bloomberg TV and Fox Business

Oct 13, 2023, 09:40 AM
GlobeNewswire Inc.

Mangoceuticals Announces the Official Launch of MangoRx Affiliate Marketing Program to Enhance and Accelerate Topline Growth

Oct 12, 2023, 09:15 AM
GlobeNewswire Inc.

Mangoceuticals Brand MangoRx Announced as Raindance Film Festival’s Headline Sponsor

Sep 14, 2023, 06:00 AM
Market Cap
6.52M
Enterprise Value
6.35M
P/E
P/B
0.48
P/S
15.74
EV / EBITDA
-0.44
EV / Sales
15.31
EPS
-1.17
Dividend Yield
0%
P/FCF
P/CF
Free Cash Flow
ROE
-149.07%
ROA
-139.03%
Debt / Equity
0
Current Ratio
0.29
Quick Ratio
0.29
Cash
0.24
Avg Volume
714.66K
Fundamentals Snapshot Price
0.38

Income Statement

Line Item 2026 Q1 2025 Q4 2025 Q3 2025 Q2 2025 Q1
Revenue 67.86K 94.36K 84.25K 168.11K 109.31K
Gross profit 59.65K 47.48K 50.9K 89.95K 84.57K
Operating income -1.76M -1.62M -7.54M -5.27M -3.81M
EBITDA -1.46M -1.04M -7.52M -4.43M -3.39M
Net income -3.7M -3.06M -7.91M -5.42M -5.13M
Basic EPS -0.22 -0.01 -0.69 -0.57 -1.12
Diluted EPS -0.22 -0.01 -0.69 -0.57 -1.12

Balance Sheet

Line Item 2026 Q1 2025 Q4 2025 Q3 2025 Q2 2025 Q1
Total assets 14.45M 16.09M 16.53M 20.84M 21.75M
Total liabilities 974.57K 890.57K 804.28K 1.6M 1.5M
Total equity 13.47M 15.2M 15.73M 19.24M 20.25M
Cash & equivalents 174.56K 1.49M 481.28K 101.02K 76.5K
Current assets 212.47K 1.55M 598.22K 117.96K 176.65K
Current liabilities 737.61K 890.57K 804.28K 1.6M 1.5M

Cash Flow

Line Item 2026 Q1 2025 Q4 2025 Q3 2025 Q2 2025 Q1
Operating cash flow -1.31M -1.08M -1.24M -1.26M -2.27M
Investing cash flow
Financing cash flow 2.08M 1.62M 1.28M 2.29M
Change in cash -1.31M 1.01M 380.31K 24.34K 10.22K
Kind Filing Date Link
edgar index 10-Q — MANGOCEUTICALS, INC. View Filing
edgar index NT 10-Q — MANGOCEUTICALS, INC. View Filing
edgar index 10-K — MANGOCEUTICALS, INC. View Filing
ten k section 10-K — business View Filing
ten k section 10-K — mda View Filing
ten k section 10-K — risk_factors View Filing
edgar index 4 — MANGOCEUTICALS, INC. View Filing
edgar index 4 — MANGOCEUTICALS, INC. View Filing
edgar index 8-K — MANGOCEUTICALS, INC. View Filing
eight k text 8-K — 8-K View Filing
form 4 Form 4 — Tiger Cub Trust View Filing
form 4 Form 4 — Tiger Cub Trust View Filing
form 4 Form 4 — Cohen Jacob D. View Filing
form 4 Form 4 — Cohen Jacob D. View Filing
form 4 Form 4 — Tiger Cub Trust View Filing
form 4 Form 4 — Cohen Jacob D. View Filing
form 4 Form 4 — Cohen Jacob D. View Filing
form 4 Form 4 — Tiger Cub Trust View Filing
form 4 Form 4 — Tiger Cub Trust View Filing
form 4 Form 4 — Tiger Cub Trust View Filing
form 4 Form 4 — Cohen Jacob D. View Filing
form 4 Form 4 — Cohen Jacob D. View Filing
form 4 Form 4 — Cohen Jacob D. View Filing
form 4 Form 4 — Tiger Cub Trust View Filing
form 4 Form 4 — Cohen Jacob D. View Filing
form 4 Form 4 — Tiger Cub Trust View Filing
edgar index 8-K — MANGOCEUTICALS, INC. View Filing
eight k text 8-K — 8-K View Filing
edgar index 8-K — MANGOCEUTICALS, INC. View Filing
eight k text 8-K — 8-K View Filing
edgar index 8-K — MANGOCEUTICALS, INC. View Filing
eight k text 8-K — 8-K View Filing
edgar index EFFECT — MANGOCEUTICALS, INC. View Filing
edgar index UPLOAD — MANGOCEUTICALS, INC. View Filing
edgar index CORRESP — MANGOCEUTICALS, INC. View Filing
edgar index S-1/A — MANGOCEUTICALS, INC. View Filing
edgar index S-1 — MANGOCEUTICALS, INC. View Filing
edgar index 8-K — MANGOCEUTICALS, INC. View Filing
edgar index 424B5 — MANGOCEUTICALS, INC. View Filing
edgar index 8-K — MANGOCEUTICALS, INC. View Filing
eight k text 8-K — 8-K View Filing
eight k text 8-K — 8-K View Filing
edgar index 4 — MANGOCEUTICALS, INC. View Filing
form 4 Form 4 — JOHNSTON EUGENE M View Filing
edgar index 4 — MANGOCEUTICALS, INC. View Filing
edgar index 8-K — MANGOCEUTICALS, INC. View Filing
eight k text 8-K — 8-K View Filing
edgar index 4 — MANGOCEUTICALS, INC. View Filing
form 4 Form 4 — JOHNSTON EUGENE M View Filing
form 4 Form 4 — JOHNSTON EUGENE M View Filing
edgar index 144 — MANGOCEUTICALS, INC. View Filing
edgar index 4 — MANGOCEUTICALS, INC. View Filing
edgar index 144 — MANGOCEUTICALS, INC. View Filing
form 4 Form 4 — Hamilton Alex P. View Filing
edgar index 8-K — MANGOCEUTICALS, INC. View Filing
edgar index 10-Q/A — MANGOCEUTICALS, INC. View Filing
edgar index 10-Q — MANGOCEUTICALS, INC. View Filing
eight k text 8-K — 8-K View Filing
edgar index 8-K — MANGOCEUTICALS, INC. View Filing
eight k text 8-K — 8-K View Filing
edgar index 8-K — MANGOCEUTICALS, INC. View Filing
eight k text 8-K — 8-K View Filing
edgar index 4 — MANGOCEUTICALS, INC. View Filing
edgar index SCHEDULE 13D/A — MANGOCEUTICALS, INC. View Filing
edgar index 8-K — MANGOCEUTICALS, INC. View Filing
edgar index 4 — MANGOCEUTICALS, INC. View Filing
edgar index 4 — MANGOCEUTICALS, INC. View Filing
edgar index 4 — MANGOCEUTICALS, INC. View Filing
edgar index 4 — MANGOCEUTICALS, INC. View Filing
form 4 Form 4 — Cohen Jacob D. View Filing
form 4 Form 4 — Tiger Cub Trust View Filing
form 4 Form 4 — Tiger Cub Trust View Filing
form 4 Form 4 — Cohen Jacob D. View Filing
form 4 Form 4 — D'Alessio Lorraine Pamela View Filing
form 4 Form 4 — Hamilton Alex P. View Filing